

## Supporting Information

### An in depth physicochemical investigation of drug-loaded core-shell UiO66 nanoMOFs

Mengli Ding<sup>a</sup>, Borja Moreira-Álvarez<sup>b\*</sup>, Francisco Calderón Celis<sup>b\*</sup>, Jose Manuel Costa-Fernández<sup>b</sup>, Jorge Ruiz Encinar<sup>b</sup>, and Ruxandra Gref<sup>a\*</sup>


**Abstract:** ICP-MS and AF4 instrumental and operational parameters, TEM images of UiO66 and CD-MO@UiO66 nanoMOFs, AF4-MALS analysis of CD-MO@UiO66-cisplatin.

**Table S1.** Operational parameters used in the FIA-ICP-MS/MS and AF4-ICP-MS/MS analyses.


ICP-MS Parameters	Flow Injection Analysis	AF4
RF Power (W)	1550	
Sampling depth (mm)	8	
Carrier gas (L/min)	1.05	1.10
Nebulizer pump (rps)	0.2	0.3
O <sub>2</sub> cell gas flow (%)	30	
OctBias (V)	-3	
Axial Acceleration (V)	1.5	
Oct RF (V)	180	
Energy discrimination (V)	-7	
Integration time (s)	0.1	

**Table S2.** AF4 operational parameters and separation program.


AF4 Parameters	
Injection volume (μL)	20
Injection time (min)	2
Tip flow rate (mL/min)	0.2
Transition time (min)	1
Initial cross flow rate (mL/min)	0.3
Cross flow linear decay (min)	10
Cross flow final constant (min)	5
Detector flow rate (mL/min)	0.3



**Figure S1.** TEM images of (A) UiO66 nanoMOFs and (B) CD-MO@UiO66.



**Figure S2.** DLS number distribution and intensity distribution of UiO66 nanoMOFs.



**Figure S3.** (A) AF4-MALS-ICP-MS/MS fractogram of CD-MO@UiO66-cisplatin, (B) MALS results obtained for the framed area and, (C) histogram of the MALS results.